Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Aisling Capital Management LP (CIK 1766721) reported $476.3M across 12 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: BBIO ($378.0M, 79.35%), SNDX ($30.8M, 6.46%), GLUE ($25.6M, 5.37%), BCAX ($11.3M, 2.38%), ($9.1M, 1.91%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | BBIO | BridgeBio Pharma Inc. (BBIO) | $378.0M | 79.35% | 5.1M | Hold |
| 2 | SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $30.8M | 6.46% | 1.3M | Hold |
| 3 | GLUE | Monte Rosa Therapeutics Inc (GLUE) | $25.6M | 5.37% | 1.6M | Added |
| 4 | BCAX | Bicara Therapeutics Inc. (BCAX) | $11.3M | 2.38% | 568,919 | Hold |
| 5 | BridgeBio Oncology Therapeutics (BBOT) | $9.1M | 1.91% | 1.0M | Added | |
| 6 | CMPS | Compass Pathways Plc (CMPS) | $7.9M | 1.66% | 1.4M | Added |
| 7 | SRRK | Scholar Rock Holding Corporation (SRRK) | $3.8M | 0.80% | 77,031 | Hold |
| 8 | BMEA | Biomea Fusion Inc (BMEA) | $3.1M | 0.66% | 2.0M | Hold |
| 9 | EPRX | Eupraxia Pharmaceuticals Inc. (EPRX) | $2.4M | 0.49% | 325,000 | New |
| 10 | URGN | Urogen Pharma Ltd. (URGN) | $1.9M | 0.41% | 108,000 | Hold |
| 11 | ACRS | Aclaris Therapeutics Inc (ACRS) | $1.6M | 0.34% | 434,455 | Hold |
| 12 | MRKR | Marker Therapeutics, Inc. (MRKR) | $422,981 | 0.09% | 325,370 | Hold |
| 13 | OKUR | OnKure Therapeutics, Inc. (OKUR) | $366,833 | 0.08% | 88,607 | Hold |
| 14 | CALC | CalciMedica, Inc. (CALC) | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31